Bispecific Immunotherapy Pumitamig Shows Strong Early Results in First‑Line Lung Cancer Trials

The joint venture between BioNTech (BNTX) and Bristol Myers Squibb (BMY) presented interim results from the dose‑optimization portion of the ROSETTA Lung‑02 trial at the American Society of Clinical Oncology meeting. The study evaluated pumitamig, a bispecific molecule that simultaneously blocks PD‑L1 and VEGF‑A, together with standard platinum‑based chemotherapy in patients with previously untreated advanced NSCLC.

In the 40 evaluable participants, overall confirmed objective response rates (cORR) reached 57.1% for non‑squamous disease and 68.4% for squamous histology, while disease control was achieved in every patient. Notably, a lower dose of pumitamig (1,400 mg) produced even higher responses—63.6% in non‑squamous and 72.7% in squamous tumors—suggesting that the bispecific may achieve optimal efficacy without maximal dosing. Response rates were robust across all PD‑L1 expression brackets: 47.6% for TPS < 1%, 77.8% for TPS 1–49%, and a full 100% for TPS ≥ 50%.

Safety data were consistent with expectations for chemo‑immunotherapy combinations. Grade 3 or higher treatment‑related adverse events occurred in roughly half of the cohort, but only about one‑quarter were attributed directly to pumitamig. Discontinuations due to toxicity were limited (9.3%), and serious immune‑mediated events were rare (4.7%). These tolerability signals are important because they indicate that adding a second checkpoint target does not dramatically increase the risk profile beyond what clinicians already manage with PD‑1/PD‑L1 inhibitors.

For investors, the trial’s early efficacy signal matters for several reasons. First, it validates the bispecific approach of targeting both immune evasion and tumor angiogenesis in a single agent—a strategy that could simplify regimens compared with separate anti‑VEGF antibodies and checkpoint inhibitors. Second, the breadth of activity across PD‑L1 levels addresses a key unmet need: patients with low or negative PD‑L1 expression currently derive limited benefit from monotherapy checkpoint blockers. If the Phase 3 data confirm these trends, pumitamig could capture market share from existing standards such as pembrolizumab plus chemo and potentially become a new backbone for first‑line NSCLC.

The upcoming Phase 3 portion of ROSETTA Lung‑02 will pit pumitamig plus chemotherapy against the current benchmark regimen of pembrolizumab with chemotherapy, using progression‑free survival (PFS) as the primary endpoint. A positive readout could accelerate regulatory filings and enable BMS to tap into a market projected to exceed $10 billion globally within the next five years. Moreover, the partnership already has two additional pivotal Phase 3 studies underway: ROSETTA Lung‑201 in unresectable stage III disease (comparing pumitamig to durvalumab after chemoradiation) and ROSETTA Lung‑202 in advanced NSCLC with high PD‑L1 expression (pumitamig versus pembrolizumab). Success across these trials would provide a multi‑line, histology‑agnostic platform that reinforces BMS’s oncology franchise.

From a valuation perspective, BMY shares are currently trading near the lower end of their 52‑week range, with analysts forecasting an average price target around $62. The upside potential embedded in pumitamig’s data could help narrow the gap between current pricing and consensus expectations. However, investors should weigh execution risk: the transition from Phase 2 response rates to statistically significant PFS or overall survival gains is not guaranteed, and any safety concerns emerging in larger cohorts could dampen enthusiasm. Additionally, competition from next‑generation bispecifics and novel antibody‑drug conjugates entering late‑stage lung cancer trials may compress pricing power.

In summary, the interim ROSETTA Lung‑02 data provide a compelling early glimpse of pumitamig’s therapeutic promise. The high response rates across histologies and PD‑L1 strata, coupled with manageable toxicity, suggest that this bispecific could fill a critical gap in first‑line NSCLC therapy. As the Phase 3 program advances, market participants will be watching closely to see whether these signals translate into durable survival benefits and regulatory approval, which could materially impact Bristol Myers Squibb’s revenue outlook and its position in the competitive immuno‑oncology landscape.